C-MET as a new therapeutic target for the development of novel anticancer drugs
Clin. transl. oncol. (Print)
; 12(4): 253-260, abr. 2010. tab, ilus
Article
in English
| IBECS
| ID: ibc-124067
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
MET is a tyrosine kinase receptor that, upon binding of its natural ligand, the hepatocyte growth factor (HGF), is phosphorylated and subsequently activates different signalling pathways involved in proliferation, motility, migration and invasion. MET has been found to be aberrantly activated in human cancer via mutation, amplification or protein overexpression. MET expression and activation have been associated with prognosis in a number of tumour types and predict response to MET inhibitors in preclinical models. Here we review the HGF/MET signalling pathway, its role in human cancer and the different inhibitory strategies that have been developed for therapeutic use (AU)
RESUMEN
No disponible
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Signal Transduction
/
Proto-Oncogene Proteins c-met
/
Antineoplastic Agents
Type of study:
Prognostic study
Limits:
Animals
/
Female
/
Humans
/
Male
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2010
Document type:
Article
Institution/Affiliation country:
Capio-Fundación Jiménez Díaz/Spain
/
Hospital del Mar/Spain
/
Institut Municipal d'Investigacions Mediques/Spain